Panacos Pharmaceuticals Inc. Presents Phase 2b Bevirimat Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

Published: Oct 27, 2008

WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (NASDAQ: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that data from the Company’s Phase 2b study of bevirimat, Panacos’ lead HIV-1 Gag maturation inhibitor, was shown in an oral presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. The key findings from Study 203 demonstrated that bevirimat appeared safe and effective in both treatment-experienced and treatment-naive HIV-positive patients, established the bevirimat dose-response curve, and prospectively confirmed factors that predict patient response to bevirimat treatment.

Back to news